Bullish
Sarepta Therapeutics is advancing towards full FDA approval for its Duchenne Muscular Dystrophy drugs, VYONDYS 53 and AMONDYS 45. The FDA has accepted...
Bullish
The FDA has accepted Sarepta's applications for Amondys 45 and Vyondys 53, setting a target decision date of February 28, 2027, for full approval of t...
Sarepta Therapeutics' future relies on regulatory decisions for its Duchenne muscular dystrophy gene therapy, Elevidys, and the development of its siR...